David R. Eyre

Changes in cartilage composition and physical properties due to stromelysin degradation.

L. Bonassar, A. Grodzinsky, D. Eyre, 1995, Arthritis and rheumatism.

Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1(I) chains of type I collagen determines the clinical phenotype.

P. Byers, J. Graham, D. Eyre, 1989, The Journal of clinical investigation.

Biochemical Markers as Surrogate End Points of Joint Disease

D. Eyre, L. Lohmander, David R. Eyre, 2008 .

Procollagen II Amino Propeptide Processing by ADAMTS-3

D. Eyre, A. Colige, D. Cohn, 2001, The Journal of Biological Chemistry.

Preliminary observations of chondral abrasion in a canine model.

R. Altman, D. Dean, L. Chun, 1992, Annals of the rheumatic diseases.

Incorporation of structurally defective type II collagen into cartilage matrix in kniest chondrodysplasia.

D. Rimoin, D. Eyre, W. Wilcox, 1998, Archives of biochemistry and biophysics.

Articular cartilage collagen: an irreplaceable framework?

D. Eyre, Jiann-Jiu Wu, M. Weis, 2006, European cells & materials.

A mutation in the alpha 3 chain of type IX collagen causes autosomal dominant multiple epiphyseal dysplasia with mild myopathy.

L. Kunkel, C. Bönnemann, D. Anthony, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.

M. Todman, J. Rousseau, A. Ko, 2011, Osteoarthritis and cartilage.

Autoreactivity against matrilin-1 in a patient with relapsing polychondritis.

D. Eyre, J. Buckner, Jiann-Jiu Wu, 2000, Arthritis and rheumatism.